{"id":10750,"date":"2021-08-09T17:47:48","date_gmt":"2021-08-09T15:47:48","guid":{"rendered":"https:\/\/www.endoscopy-campus.com\/?post_type=ec-news&#038;p=10750"},"modified":"2021-08-09T17:47:49","modified_gmt":"2021-08-09T15:47:49","slug":"only-80-eradication-rates-of-barretts-esophagus-with-long-term-follow-up-of-endoscopic-therapy-studies","status":"publish","type":"ec-news","link":"https:\/\/www.endoscopy-campus.com\/en\/ec-news\/only-80-eradication-rates-of-barretts-esophagus-with-long-term-follow-up-of-endoscopic-therapy-studies\/","title":{"rendered":"Only 80% Eradication Rates of Barrett\u2019s Esophagus With Long-Term Follow-Up of Endoscopic Therapy Studies"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Patients with high-grade dysplasia and\/or early cancer in Barrett\u2019s esophagus (BE) are treated with endoscopic therapy (BET), with the goal of complete eradication of all intestinal metaplasia (CE-IM) and neoplasia (CE-N). BET is a set of endoscopic techniques, including endoscopic mucosal resection, usually followed by mucosal ablative procedures, such as radiofrequency ablation, cryotherapy, or argon plasma coagulation. Although immediate post-BET results have shown to be excellent, it is unclear how durable the effect of BET is in long-term follow-up. This systematic review and meta-analysis evaluated the long-term efficacy of BET using stringent criteria to include studies that followed patients with BE for a minimum of 2 years after achieving confirmed CE-IM or CE-N, as well as studies with clearly defined surveillance intervals and systematic sampling protocols.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A total of 8 studies met criteria and included 794 patients who underwent BET, of whom 658 completed therapy and 598 completed follow-up. The pooled estimate of patients achieving CE-N was 95.9% (91.8%-94.9%;&nbsp;<em>I2<\/em>=95.9%), with an intent-to-treat pooled estimate of 84.5% (69.8%-94.9%;&nbsp;<em>I2<\/em>=95.9%). The overall pooled estimate of CE-IM was 90.9% (83%-96.6%;&nbsp;<em>I2<\/em>=89.1%), with an intent-to-treat pooled estimate of 79.3% (64.3%-91.1%;&nbsp;<em>I2<\/em>=95.5%). Of the 598 patients followed for a mean duration of 3.4 years (range, 27-69.7 months), overall pooled rates of durable CE-N and CE-IM were 89% (73.4%-98.2%;&nbsp;<em>I2<\/em>=96%) and 77.8% (65.6%-88%;&nbsp;<em>I2<\/em>=90.9%), with intent-to-treat analysis showing 70% (49.5%-87%;&nbsp;<em>I2<\/em>=97.1%) and 62.9% (44.4%-79.7%;&nbsp;<em>I2<\/em>=96.4%) for CE-N and CE-IM, respectively. Only 2 studies provided data from beyond 5 years of follow-up, with rates of 54.3% (41.5%-67%) and 50% (41.5%-58.5%) for CE-N and CE-IM, respectively.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Patients with high-grade dysplasia and\/or early cancer in Barrett\u2019s esophagus (BE) are treated with endoscopic therapy (BET), with the goal of complete eradication of all intestinal metaplasia (CE-IM) and neoplasia (CE-N). BET is a set of endoscopic techniques, including endoscopic mucosal resection, usually followed by mucosal ablative procedures, such as radiofrequency ablation, cryotherapy, or argon &#8230; <a title=\"Only 80% Eradication Rates of Barrett\u2019s Esophagus With Long-Term Follow-Up of Endoscopic Therapy Studies\" class=\"read-more\" href=\"https:\/\/www.endoscopy-campus.com\/en\/ec-news\/only-80-eradication-rates-of-barretts-esophagus-with-long-term-follow-up-of-endoscopic-therapy-studies\/\" aria-label=\"Read more about Only 80% Eradication Rates of Barrett\u2019s Esophagus With Long-Term Follow-Up of Endoscopic Therapy Studies\">Read more<\/a><\/p>\n","protected":false},"template":"","categories":[1768,1791],"tags":[1944,1929,1936,1937,2892,2891,2098,2139],"class_list":["post-10750","ec-news","type-ec-news","status-publish","hentry","category-asge-journal-scan","category-esophagus","tag-barretts-esophagus-2","tag-be","tag-bet","tag-ce-im","tag-ce-n","tag-complete-eradication-of-all-intestinal-metaplasia","tag-esophagus-2","tag-neoplasia-2"],"_links":{"self":[{"href":"https:\/\/www.endoscopy-campus.com\/en\/wp-json\/wp\/v2\/ec-news\/10750","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.endoscopy-campus.com\/en\/wp-json\/wp\/v2\/ec-news"}],"about":[{"href":"https:\/\/www.endoscopy-campus.com\/en\/wp-json\/wp\/v2\/types\/ec-news"}],"wp:attachment":[{"href":"https:\/\/www.endoscopy-campus.com\/en\/wp-json\/wp\/v2\/media?parent=10750"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.endoscopy-campus.com\/en\/wp-json\/wp\/v2\/categories?post=10750"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.endoscopy-campus.com\/en\/wp-json\/wp\/v2\/tags?post=10750"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}